Pancreatic cancer is an aggressive malignancy with increasing incidence and poor
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …

Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among all
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a notably poor
prognosis, in urgent need of improved treatment strategies. The desmoplastic PDAC tumor …

Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …

Metastasis and tumor progression are the major cause of death in patients suffering from
pancreatic ductal adenocarcinoma. Tumor growth and especially dissemination are typically …

Cancer-associated fibroblasts (CAFs) are considered to play a fundamental role in
pancreatic ductal adenocarcinoma (PDAC) progression and chemoresistance. Patient …

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies and is
characterized by a unique tumor microenvironment (TME) consisting of an abundant stromal …

A new series of eighteen imidazo [2, 1-b][1, 3, 4] thiadiazole derivatives was efficiently
synthesized and screened for antiproliferative activity against the National Cancer Institute …

Cutaneous leishmaniasis (CL) is a significant public health problem caused by different
species of Leishmania parasites. Due to low skin permeability, the development of an …

Pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC/PC)) has been an aggressive
disease that is associated with early metastases. It is characterized by dense and …